196 related articles for article (PubMed ID: 37222198)
21. Health-related quality of life following neoadjuvant chemoradiotherapy versus perioperative chemotherapy and esophagectomy for esophageal cancer: a European multicenter study.
Schuring N; Markar SR; Hagens ERC; Jezerskyte E; Sprangers MAG; Lagergren P; Johar A; Gisbertz SS; van Berge Henegouwen MI;
Dis Esophagus; 2023 Mar; 36(4):. PubMed ID: 36241253
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma.
Fick CN; Dunne EG; Sihag S; Molena D; Cytryn SL; Janjigian YY; Wu AJ; Worrell SG; Hofstetter WL; Jones DR; Gray KD
Ann Thorac Surg; 2024 Feb; ():. PubMed ID: 38408631
[TBL] [Abstract][Full Text] [Related]
23. (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the West.
Wilke H; Lordick F; Meyer HJ; Stahl M
Dig Surg; 2013; 30(2):112-8. PubMed ID: 23867587
[TBL] [Abstract][Full Text] [Related]
24. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
[TBL] [Abstract][Full Text] [Related]
25. Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer.
Liepa AM; Cui ZL; Beyrer JK; Hadden EL; Chatterjee A
Future Oncol; 2023 Jun; 19(18):1277-1291. PubMed ID: 37194743
[No Abstract] [Full Text] [Related]
26. Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes.
Jones JO; Smyth EC
Cancer Treat Rev; 2020 Mar; 84():101950. PubMed ID: 31918022
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
28. Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer.
Bolm L; Käsmann L; Paysen A; Karapetis C; Rades D; Wellner UF; Keck T; Watson DI; Hummel R; Hussey DJ
Anticancer Res; 2018 Jun; 38(6):3231-3242. PubMed ID: 29848670
[TBL] [Abstract][Full Text] [Related]
29. Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction.
Ku GY; Ilson DH
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1953-64. PubMed ID: 19046115
[TBL] [Abstract][Full Text] [Related]
30. Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers.
Davern M; Lysaght J
Cancer Lett; 2020 Dec; 495():89-99. PubMed ID: 32950619
[TBL] [Abstract][Full Text] [Related]
31. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
32. Role of neoadjuvant therapy for esophageal adenocarcinoma.
Ku GY; Ilson DH
Surg Oncol Clin N Am; 2009 Jul; 18(3):533-46. PubMed ID: 19500742
[TBL] [Abstract][Full Text] [Related]
33. Optimal management of gastroesophageal junction cancer.
Greally M; Agarwal R; Ilson DH
Cancer; 2019 Jun; 125(12):1990-2001. PubMed ID: 30973648
[TBL] [Abstract][Full Text] [Related]
34. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
Cohen DJ; Leichman L
J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
[TBL] [Abstract][Full Text] [Related]
35. Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs).
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Nowak K; Kieser M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Schuhmacher C; Urba S; van de Velde C; Walsh TN; Ychou M; Jensen K
Eur J Surg Oncol; 2017 Aug; 43(8):1550-1558. PubMed ID: 28551325
[TBL] [Abstract][Full Text] [Related]
36. Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers.
Ku GY
Surg Oncol Clin N Am; 2017 Apr; 26(2):241-256. PubMed ID: 28279467
[TBL] [Abstract][Full Text] [Related]
37. Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers.
Baxter MA; Middleton F; Cagney HP; Petty RD
Br J Cancer; 2021 Oct; 125(8):1068-1079. PubMed ID: 34230609
[TBL] [Abstract][Full Text] [Related]
38. [Current status and prospect of perioperative therapy for locally advanced gastric cancer].
Zhu ZG
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):101-106. PubMed ID: 33508913
[TBL] [Abstract][Full Text] [Related]
39. Innovative drugs and strategies in the treatment of upper gastrointestinal tract carcinomas.
Menges M; Hoehler T
Onkologie; 2004 Feb; 27(1):47-53. PubMed ID: 15007248
[TBL] [Abstract][Full Text] [Related]
40. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Kokka F; Bryant A; Brockbank E; Powell M; Oram D
Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
